Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04669314
Other study ID # AUTF-Hemangioma
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2020
Est. completion date October 30, 2020

Study information

Verified date December 2020
Source Ankara University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Operations performed for liver hemangioma between January 2017 and December 2018 will be retrospectively analyzed.


Description:

Operations performed for liver hemangioma at Ankara University Hospitals will be retrospectively analyzed. Patient and disease characteristics including demographics, laboratory tests, imaging studies, type of surgical approach and outcomes including postoperative laboratory tests, record of complications, duration of hospital stay will be reviewed. Complications were classified according to Clavien-Dindo classification. The patients were informed about the surgeries in advance and their informed consents about surgeries and data collection for scientific purposes were obtained. Datafile will be anonymized before analysis and original file will be destroyed. Outcomes such as complications, hospital stay, blood transfusion and mortality will be compared between groups created according to type of surgery, lesion size, preoperative laboratory values and demographic features. Variables for prediction of better outcomes are expected to be discovered.


Recruitment information / eligibility

Status Completed
Enrollment 69
Est. completion date October 30, 2020
Est. primary completion date October 20, 2020
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients underwent surgery for liver hemangioma Exclusion Criteria: - Cases lacking of more than 20% of critical data

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Liver resection or enucleation for liver hemangioma
Operations in which the hemangioma is selectively removed from the liver parenchyma border are named enucleation, and the operations in which the hemangioma is removed anatomically or non-anatomically with some liver parenchyma surrounding it are named liver resection

Locations

Country Name City State
Turkey Ankara University Ibni Sina Hospital Ankara

Sponsors (1)

Lead Sponsor Collaborator
Ankara University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complications Complications after surgery for hemangioma will be collected from records and and will be classified according to 'The Clavien-Dindo Classification of Surgical Complications'. The classification grades are ranging between Grade 1(better) which indicates minor deviation from normal postoperative course and Grade 5 (worst) which means death as a complication. Complications reported within 3 months after surgery will be evaluated within 15 days after completion of data collection
Secondary Hospital stay Length of hospital stay postoperatively Hospital stay starting with operation and ends with discharge will be compared within 15 days after completion of data collection
Secondary Transfusion Rate of erythrocyte transfusion Erythrocyte transfusion during surgery will be analyzed within 15 days after completion of data collection
See also
  Status Clinical Trial Phase
Completed NCT03649113 - Percutaneous Sclerotherapy of Symptomatic Liver Hemangioma With Bleomycin Phase 1
Recruiting NCT03633747 - Efficacy Evaluation of Propranolol Treatment of Hepatic Hemangioma Phase 1/Phase 2